WAVEMAN · COMPANY

BMY · Bristol Myers Squibb Co

LIVE

TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

BMY

Name: BRISTOL MYERS SQUIBB CO (BMY) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

BRISTOL MYERS SQUIBB CO

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0000014272

CONGRESS · 1FORM 144 · 1☆ WATCH

INSIDER NET · 180D

-$1.9M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

1,179

13F, latest reported quarter

REVENUE GROWTH

-0.2%

XBRL, annual

NET MARGIN

14.6%

CONVERSIONS · 180D

codes C/M, not in net · $1.2M priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$1.9M over 180 days

-$33.8K over 90 days

below 66% of Pharma & Biotech

CONGRESS

1 member bought in the last year

the lowest in Pharma & Biotech

FUNDS

1,179 funds added or opened last quarter

more than 99% of Pharma & Biotech

REVENUE

-0.2% year over year

below 56% of Pharma & Biotech

MARGIN

14.6% net margin

more than 85% of Pharma & Biotech

BUYBACKS

no share repurchases reported

SHORT

2.6% of shares outstanding short · 4.6 days to cover · settled 2026-07-31

below 60% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

1,179 funds added or opened positions in the latest 13F quarter, of 2,519 holders.

1 member of Congress reported buying it this year.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +47.7%

+47.7%12M

INSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $1.9M sold by insiders over 180 days, 1,179 funds added last quarter, 1 Congress member(s) bought in 12 months, $33.8K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, BRISTOL MYERS SQUIBB CO insiders sold a net $1.9M of stock across 49 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

Holzer Phil M

SVP and Controller

SELL

2026-08-25

500.0

$33.8K

Elkins David V

EVP, Chief Financial Officer

SELL

2026-04-01

25,519.0

$1.6M

Elkins David V

EVP, Chief Financial Officer

SELL

2026-04-01

4,481.0

$278.0K

Elkins David V

EVP, Chief Financial Officer

SELL

2025-09-02

56,000.0

$2.7M

Short Bartie Wendy

EVP, Corporate Affairs

SELL

2025-08-02

378.0

$16.7K

49 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 44 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

180,384,994.0 sh

$10.4B

VANGUARD CAPITAL MANAGEMENT LLC

133,337,856.0 sh

$7.7B

STATE STREET CORP

102,408,940.0 sh

$5.9B

JPMORGAN CHASE & CO

71,713,465.0 sh

$4.2B

CHARLES SCHWAB INVESTMENT MANAGEMENT INC

67,595,177.0 sh

$3.9B

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

Holzer Phil M

FILED 2026-08-25

$33.8K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

First Trust Nasdaq Pharmaceuticals ETF

$2.1M POSITION · AS OF 2026-03-31

7.4%

Independent Franchise Partners US Equity Fund

$96.2M POSITION · AS OF 2026-03-31

6.3%

Invesco S&P Ultra Dividend Revenue ETF

$53.1M POSITION · AS OF 2026-02-28

5.5%

Integrity Dividend Summit Fund

$787.7K POSITION · AS OF 2026-04-30

5.3%

Horizon Kinetics Medical ETF

$930.9K POSITION · AS OF 2026-03-31

5.1%

Calvert Focused Value Fund

$569.7K POSITION · AS OF 2026-03-31

4.7%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 519 registered trials, 190 still enrolling or running — a status change here is dated weeks before the press release

122

Phase 1

25 ACTIVE

Phase 2

14 ACTIVE

102

Phase 3

51 ACTIVE

Phase 4

7 ACTIVE

Early Phase 1

0 ACTIVE

145

Not applicable

66 ACTIVE

Multi-phase

27 ACTIVE

What changed recently

A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

2026-09-02 · Recruiting → Active Not Recruiting

PHASE1,PHASE2

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Corporate PAC

FEC · the company-connected political action committee's own receipts and spending — committee totals only, never individual donors

Bristol-Myers Squibb Company Political Action Committee

CYCLE 2026 · $598K SPENT

$632.0K

FEDERAL ELECTION COMMISSION · MATCHED BY THE PAC'S CONNECTED ORGANISATION

Executive pay vs shareholder return · Dr. Chris Boerner

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2025

$21.9M

$16.9M

$9.2M

+5%

+98%

2024

$18.8M

$21.2M

$7.7M

+5%

+54%

2022

$20.1M

$35.1M

$7.0M

+23%

+39%

2021

$19.8M

$16.5M

$7.1M

+3%

+26%

2020

$20.2M

$17.6M

$7.1M

+0%

+2%

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$48.2B	$48.3B	$45.0B	$46.2B
NET INCOME	$7.1B	$-8.9B	$8.0B	$6.3B
EPS (DILUTED)	3.46	-4.41	3.86	2.95
OPERATING CASH FLOW	$14.2B	$15.2B	$13.9B	$13.1B
CASH	$10.2B	$10.3B	$11.5B	$9.1B
LONG-TERM DEBT	$42.9B	$47.6B	$36.7B	$35.1B
BUYBACKS	$0	$0	$5.2B	$8.0B
DIVIDENDS PAID	$5.0B	$4.9B	$4.7B	$4.6B

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE